Skip to content

Early low-dose hydrocortisone on survival without severe bronchopulmonary dysplasia in infants born <26 weeks gestational age: a double-blind, placebo-controlled, multicentre, randomised trial

Early low-dose hydrocortisone on survival without severe bronchopulmonary dysplasia in infants born <26 weeks gestational age: a double-blind, placebo-controlled, multicentre, randomised trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098918
Enrollment
Unknown
Registered
2025-03-15
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchopulmonary dysplasia

Interventions

hydrocortisone:Intravenous administration of hydrocortisone within 24 hours after birth.
placebo:An equal amount of physiological saline was administered intravenously within 24 hours after birth.

Sponsors

Shenzhen Maternity & Child Healthcare Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
0.4 Years to 2.2 Years

Inclusion criteria

Inclusion criteria: 1.Gestational age less than 26 weeks 2.Parental consent had been obtained

Exclusion criteria

Exclusion criteria: 1.Congenital malformations affecting pulmonary function (e.g., congenital surfactant protein deficiencies, congenital diaphragmatic hernia,Pierre Robin Syndrome ,Chromosomal defects (e.g., trisomy 13, 18, 21). 2.Parents refuse

Design outcomes

Primary

MeasureTime frame
survival without moderate or severe bronchopulmonary dysplasia;

Secondary

MeasureTime frame
Failure to extubate at days14, 21 and 28;Total duration of mechanical ventilation and supplemental oxygen;Need for late rescue treatment with dexamethasone;Use of "rescue treatment" with hydrocortisone outside the study protocol;Types, dosages, and durations of vasoactive drugs used within 14 days after birth;Intraventricular hemorrhage > =grade ? and/ or periventricular leucomalacia;Nosocomial infection, including cultured proven sepsis, meningitis, and pneumonia. Culture-proven infection is defined as a positive culture obtained from sputum, urine, blood, or cerebrospinal fluid of infants with clinical signs of infection, and pneumonia will be confirmed by abnormal lung examination (such X-ray, CT);Neonatal necrotizing enterocolitis ;Spontaneous intestinal perforation;Hemodynamic significant patent ductus arteriosus for which medical intervention or surgical ligation is needed;Retinopathy of prematurity (ROP);Anthropometric indices. Body length, head circumference, and body weight at 28 postnatal days ,36 weeks of PMA ,40 weeks PMA and at discharge;Blood pressure fluctuations within 14 days after birth;Metabolic disorders occur within 14 days after birth;Hospitalization days;

Countries

China

Contacts

Public ContactYang Chuan Zhong

Department of Neonatology, Shenzhen Maternity & Child Healthcare Hospital,GuangGong Province ,China

yangczgd@163.com+86 135 0005 1711

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026